Glenmark Pharmaceuticals share price
Glenmark Pharmaceuticals Ltd. · NSE: GLENMARK · Healthcare
Price, one year
Price range
- Open
- ₹2,196.00
- High
- ₹2,203.80
- Low
- ₹2,101.60
- Previous close
- ₹2,198.50
- Volume
- 8.9 L
- Market cap
- ₹61,147 Cr
Key statistics
Results to 30 Jun 2026 · Consolidated- P/E (TTM)
- 34.0
- Price to book
- 5.8
- Return on equity
- 14.2%
- EPS (TTM)
- ₹63.71
- Book value / share
- ₹372.47
- Debt to equity
- 0.00
- Revenue (TTM)
- ₹17,737 Cr
- Net profit (TTM)
- ₹1,496 Cr
- Sales growth, YoY
- +23.1%
- Profit growth, YoY
- +930.3%
- Operating margin
- 27.0%
- Net margin
- 8.4%
- Sales CAGR, 3 years
- +9.3%
- Profit CAGR, 3 years
- −93.6%
- Promoter holding
- 46.65%
- Promoter shares pledged
- 0.00%
Shareholding pattern
% of shares| Holder | Mar 2026 | Jun 2026 | Sep 2026 |
|---|---|---|---|
| Promoters | 46.65 | 46.65 | 46.65 |
| Foreign institutions | 20.34 | 20.89 | 21.51 |
| Domestic institutions | 19.29 | 18.60 | 17.64 |
| Mutual funds | 16.80 | 16.76 | 15.61 |
| Retail and others | 10.32 | 10.60 | 10.44 |
Futures and options
23 Oct 2026- Lot size
- 375
- Put-call ratio (OI)
- 0.52
- Max pain
- ₹2,220.00
- Highest call OI strike
- 2,300.00
- Highest put OI strike
- 2,100.00
- ATM implied volatility
- 34.0% IV rank 61
- Futures basis
- −1.34%
- Rollover
- 64.8%
Futures open interest, last sessions
| Date | Build-up | Price | OI change |
|---|---|---|---|
| 23 Oct | Long unwinding | −2.66% | −2.47% |
| 22 Oct | Short covering | +0.48% | −0.49% |
| 21 Oct | Long unwinding | −1.23% | −0.39% |
| 19 Oct | Short buildup | −0.87% | +0.31% |
| 16 Oct | Short buildup | −1.10% | +2.51% |
Option figures are for the 27 Oct 2026 expiry.
Results and announcements
Latest results (quarter to 30 Jun 2026) filed 31 Jul 2026. results: 5 Nov 2026.
Peers in Healthcare
All Healthcare stocks| Company | Price | Change |
|---|---|---|
| Sun Pharmaceutical IndustriesSUNPHARMA | ₹1,748.00 | −0.57% |
| Divi's LaboratoriesDIVISLAB | ₹8,950.00 | −2.31% |
| Torrent PharmaceuticalsTORNTPHARM | ₹4,524.40 | −1.97% |
| Zydus LifesciencesZYDUSLIFE | ₹1,129.40 | −0.49% |
| Apollo Hospitals EnterpriseAPOLLOHOSP | ₹7,730.00 | +1.65% |
| CiplaCIPLA | ₹1,338.00 | +0.53% |
| Laurus LabsLAURUSLABS | ₹1,970.00 | −1.62% |
| Dr. Reddy's LaboratoriesDRREDDY | ₹1,229.50 | −0.77% |
| Mankind PharmaMANKIND | ₹2,212.60 | −2.77% |
| Aurobindo PharmaAUROPHARMA | ₹1,571.70 | −2.43% |
Frequently asked questions
What is the share price of Glenmark Pharmaceuticals today?
Glenmark Pharmaceuticals (NSE: GLENMARK) was at ₹2,166.60 on 23 Oct 2026, a change of −1.45% from the previous close.
What are the 52-week high and low of Glenmark Pharmaceuticals?
Over the last 52 weeks Glenmark Pharmaceuticals traded between ₹1,792.60 and ₹2,537.60 (daily highs and lows on NSE on 23 Oct 2026).
What is the market capitalisation of Glenmark Pharmaceuticals?
About ₹61,147 Cr at the latest price, with a P/E of 34.0, a price-to-book of 5.8, a return on equity of 14.2%. Ratios use the company's latest reported results.
Who owns Glenmark Pharmaceuticals shares?
According to the shareholding pattern filed with the exchange at the end of the quarter to 30 Sep 2026, promoters held 46.65%, foreign institutions 21.51%, domestic institutions 17.64%.
Is Glenmark Pharmaceuticals traded in futures and options?
Yes, GLENMARK is in NSE's futures and options segment. The lot size is 375 shares.
Which sector and indices does Glenmark Pharmaceuticals belong to?
NSE classifies Glenmark Pharmaceuticals under Healthcare; it is a member of Nifty 500.
Follow Glenmark Pharmaceuticals with research you can verify. Add it to a watchlist, see screens and charts, and get calls from SEBI-registered research analysts with recorded track records.
Start free trial